Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: Roivant - The Untold Story

Inhaled Drug Cut Blood Vessel Resistance in the Lungs Fifty Six Percent in a Trial of 135 Patients

An inhaled drug met its main goal in a 135-patient mid-stage trial for pulmonary hypertension linked to interstitial lung disease.

Medical Daily

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary hypertension data for mosliciguat and continued preparation for a potential brepocitinib launch in d

MarketBeat

Immunovant Q4 Earnings Call Highlights

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna. Matthew Klein, CEO of Roivant, said the company has had “a pret

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

This Red-Hot Biopharma Stock Could Fizzle Out Soon

Roivant Sciences (ROIV) shows strong technical momentum and is trading at new all-time highs. Shares are up 52% over the past year and 20% in the last month. ROIV has a 100% “Buy” opinion from Barchart and a Trend Seeker “Buy” signal. Despite the price gains, Roivant lacks consistent revenue...

Barchart

Vivek Ramaswamy is furiously defending his business ties in China. What are they?

‘Vivek’s first business had a subsidiary in China’ which was closed ‘as the risks of doing business in China became apparent,’ Ramaswamy spokesperson says

The Independent UK

Smoke and mirrors: I’ve been debating Vivek Ramaswamy for 2 years. Here’s how I got past his diversionary tactics

Vivek Ramaswamy's fiercest critic, Yale Professor Jeffrey Sonnenfeld, has studied the presidential hopeful's debate strategies–and his business record.

Fortune

Vivek Ramaswamy: The mini Trump making waves in the Republican contest

Broadly viewed as the winner of the Republican presidential debate, the ‘anti-woke’ tech bro has broken out from the GOP pack

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

‘He’s an insider’: Ramaswamy’s deep ties to rightwing kingpins revealed

Republican candidate brands himself as an ‘outsider’ but has close links to prominent figures Leonard Leo and Peter Thiel

The Guardian - US

How Vivek Ramaswamy, the surprise GOP debate star, made his fortune and triggered his critics

He bills himself as an iconoclast ready to shake up the Republican Party after making millions trying to do the same in the biotech industry.

Fortune

Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype

Yale's Sonnenfeld and Tian retrace presidential hopeful Vivek Ramaswamy's business record.

Fortune

Roivant, Pfizer Unveil Latest Spinout Focused On Autoimmune Diseases

Roivant Sciences Ltd (NASDAQ:ROIV) and Pfizer Inc (NYSE:PFE) unveiled Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant was established in September 2021 through a transaction between Roivant and Pfizer. Pfizer licensed oral and topical brepocitinib's global development rights and US and Japan commercial rights to Priovant. Pfizer holds a 25%…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.